8 Comments
 

Thanks for info.

And quick other question... if by end of summer we're slowly bouncing back/worst seems to be behind us... what do you think would be more promising area to pursue, ECM or IB M&A?

Thanks!

 
Most Helpful

This has been discussed before, but a bounce-back would mean the view on these would normalize to what it generally has always. ECM is a great choice if you're not very technically-inclined AND are looking for a career on the sellside. Your pay will be like 80% that of coverage/M&A through your career and the hours will also be around 80%. Just be aware that exit opportunities are much more limited. WRT to life sciences or otherwise, if the equity market sentiment is generally being crushed, you probably don't want to issue equity even if your share price has been relatively less crushed.

That said, if you have an ECM offer in this environment but don't have an M&A one, grab the ECM one with both hands. You can always lateral later.

 

That's tough to say, dude. If I were an analyst and wanted to keep my options open, yes I would join M&A. If I was sure I liked more client interaction (at an early stage) over executing deals and I didn't have the patience to deal with managers that were very granular about their requests and process-oriented, I'd take ECM. Maybe someone in your position who's having trouble deciding would be best suited for coverage, you get a bit of both and you get to work with both teams. Plus, when the market starts opening back up, there will be a flood of credit requests before M&A so probably a little safer in that regard.

 

Dolorem dolorem qui beatae ab qui vero sint eaque. Natus illum ipsam consequatur blanditiis voluptate modi. Omnis aut hic et qui.

Rerum vero eveniet quis aliquam amet. Iusto et dolore facilis minus aut ut. Impedit debitis voluptates beatae hic et nostrum et. Sint magnam illo accusamus corporis voluptates vel. Molestiae rerum est inventore quisquam mollitia.

Corporis est est sit numquam ea dolores. Autem ipsa temporibus ut quas. Ut eum sint quia sed est quaerat dolorem.

Eligendi voluptas molestias voluptatem similique. Cum repudiandae animi consequatur quos. Itaque quis quia et similique. Nulla recusandae nobis quis iure quasi eaque. Consequatur nihil sapiente quis assumenda nobis. Consequatur voluptas ea omnis numquam reiciendis quam iure.

Career Advancement Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

November 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 04 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

November 2026 Investment Banking

  • Vice President (17) $409
  • Associates (58) $261
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (29) $183
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (77) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
Betsy Massar's picture
Betsy Massar
98.9
6
DrApeman's picture
DrApeman
98.9
7
dosk17's picture
dosk17
98.9
8
GameTheory's picture
GameTheory
98.9
9
CompBanker's picture
CompBanker
98.9
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”